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Abstract
Background: Monitoring of the appearance of left ventricular hypertrophy (LVH) by echocardiography is currently
recommended for in the management of children with End-stage renal disease (ESRD). In order to investigate the
validity of this method in ESRD children, we assessed the intra- and inter-observer reproducibility of the diagnosis
LVH.
Methods: Echocardiographic measurements in 92 children (0–18 years) with ESRD, made by original analysists,
were reassessed offline, twice, by 3 independent observers. Smallest detectable changes (SDC) were calculated for
continuous measurements of diastolic interventricular septum (IVSd), Left ventricle posterior wall thickness (LVPWd),
Left ventricle end-diastolic diameter (LVEDd), and Left ventricle mass index (LVMI). Cohen’s kappa was calculated to
assess the reproducibility of LVH defined in two different ways. LVHWT was defined as Z-value of IVSd and/or
LVPWd>2 and LVHMI was defined as LVMI> 103 g/m
2 for boys and >84 g/m2 for girls.
Results: The intra-observer SDCs ranged from 1.6 to 1.7 mm, 2.0 to 2.6 mm and 17.7 to 30.5 g/m2 for IVSd,
LVPWd and LVMI, respectively. The inter-observer SDCs were 2.6 mm, 2.9 mm and 24.6 g/m2 for IVSd, LVPWd and
LVMI, respectively. Depending on the observer, the prevalence of LVHWT and LVHMI ranged from 2 to 30% and from
8 to 25%, respectively. Kappas ranged from 0.4 to 1.0 and from 0.1 to 0.5, for intra-and inter- observer
reproducibility, respectively.
Conclusions: Changes in diastolic wall thickness of less than 1.6 mm or LVMI less than 17.7 g/m2 cannot be
distinguished from measurement error in individual children, even when measured by the same observer. This
limits the use of echocardiography to detect changes in wall thickness in children with ESRD in routine practice.
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Background
Cardiovascular disease is the leading cause of death in
patients with end-stage renal disease (ESRD) [1,2]. In Ju-
venile ESRD, the mortality associated with cardiac dis-
ease is reported to be 500–1000 times higher than in the
general age-matched population [3]. Left ventricular
hypertrophy (LVH) is an indicator of cardiovascular dis-
ease and is independently associated with an increased
mortality in adults with ESRD [4]. Echocardiography
studies have shown that patients with ESRD have abnor-
malities of both left ventricular (LV) structure and func-
tion [5]. Several factors may be responsible for cardiac
disease in ESRD, such as hypertension, anemia,
hyperphosphatemia, and a high parathyroid hormone
(PTH) [6]. In adult-onset ESRD, therapeutic interven-
tions, such as an increase of the dialysis frequency and a
stricter control of hypertension, hyperphosphatemia and
anemia have been investigated to reduce cardiac mortal-
ity in patients with LVH [7]. Recently, Mitsnefes et al.
emphasized the importance of frequent dialysis in chil-
dren [8]. Small single-center studies have shown clinical
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improvements in LVH and function when children receive
dialysis more frequently than the traditional, thrice-weekly
schedule [9,10]. Timely detection of cardiovascular disease
in children with ESRD would therefore give an opportun-
ity for targeted intervention in the high-risk patients,
thereby preventing cardiovascular morbidity and mortality
in early adulthood.
LVH, diagnosed with echocardiography, is considered to
be a reliable surrogate outcome marker for cardiac disease
in ESRD. Only recently, Chavers et al. have proposed the
performance of periodic routine echocardiography in all
children with ESRD, to detect cardiac disease at an early
stage [11]. In the Netherlands, Belgium and Germany, the
most widely used definition of LVH in children is based
on the M-mode echocardiographic measurement of the
interventricular septum thickness (IVSd) and left ventricu-
lar posterior wall in diastole (LVPWd). In the Netherlands,
there are normal values for Dutch healthy children
according to weight [12]. In many clinical trials and epi-
demiological studies LVH was defined based on the LV
Mass (LVM) [13,14]. The interpretation of the LVM in
children is challenging because such values need to be
appropriately indexed for body size. Various different
methods of indexing LVM to body size have been
reported, including adjustment for body surface area
(BSA) [15] and height2.7 [16,17]. The definition of LVH is
a matter of ongoing controversy [17,18], especially in pos-
sibly growth-retarded children [19,20].
In a project on quality assessment in children with
end-stage renal disease, the RICH-Q project (Renal
Insufficiency Therapy in Children: Quality Assessment
and Improvement) [21], in which all Dutch centers for
pediatric renal replacement therapy participate, we ob-
served an unexpectedly large variation in the prevalence
of LVH, using one definition, among all the Dutch cen-
ters. This raised questions about the reliability of the
measurements. We therefore decided to investigate the
intra- and inter-observer reproducibility of the mea-
surements of left ventricular wall thicknesses during
echocardiography and of the diagnosis LVH.
Methods
Study participants
We included all children (0–18 years) treated with renal
replacement therapy (RRT) between August 1st 2007 and
January 1st 2011 in the Netherlands in the study. Written
informed consent from the parents and/or the partici-
pants and approval from the ethical boards of all partici-
pating hospitals (Academic Medical Center, Amsterdam,
Erasmus Medical Center Rotterdam, University Medical
Center St Radboud Nijmegen) were obtained. For patients
whose parents have provided informed consent, data on
the routinely performed pediatric echocardiography are
registered centrally in the RICH-Q project [21].
Data collection
We reviewed one echocardiogram per subject. The
recording and analysis of the echocardiograms had been
performed by pediatric cardiologists (“original analysts”)
in all 4 Dutch centers using either Vivid 7 (GE Medical
Systems, Wauwatosa, WI) or Philips Sonos 5500,
(Medical Systems, Andouver) ultrasound systems. Two-
dimensionally guided M-mode echocardiography was
performed from a parasternal long- axis view. Inter-
ventricular septum thickness in diastole (IVSd) in mm, left
ventricular posterior wall thickness in diastole (LVPWd)
in mm and left ventricular end-diastolic diameter (LVEDd)
in mm were measured at end-diastole at the level just
below the mitral valve leaflets. A simultaneous electrocar-
diogram (ECG) was used for the timing of the measure-
ments in the cardiac cycle. The diastolic wall thickness
was measured at the onset of the QRS wave of the ECG
[22]. Digital images were stored and analyzed offline in
the Emma Children's Hospital, Amsterdam, using the
same device (EchoPac 108.1.5 General Electric Medical
Systems, by three independent observers. Observers 1
and 2 were pediatric cardiologists, each with more than
12 years of experience in interpreting pediatric echocar-
diograms. Observer 3 was a research physician specifically
trained in echocardiography. Each variable, i.e. IVSd,
LVPWd and LVEDd, was measured three times and the
mean was calculated.
LV mass was calculated using the following equation: LV
mass (grams) = 0.8 (1.04 ([LVEDd + IVSd + LVPWd]3 –
[LVEDd]3)) + 0.6 g [23]. To account for body size, the LV
mass index (LVMI) (g/m2) was calculated by dividing LV
mass by body surface area (BSA). Two definitions were
used for diagnosing LVH, one is based on the wall thick-
nesses of IVSd and LVPWd (LVHWT) and the other on
LVMI (LVH MI). LVHWT was defined as a Z-score of either
IVSd or LVPWd > + 2 based on a set of normal values of
healthy Dutch children, corrected for weight, from Over-
beek et al. [12]. LVHMI was defined as LVMI > 103 g/m
2
for boys and > 84 g/m2 for girls [16]. Observers 1, 2 and 3
reassessed all echocardiograms in a randomly different
order after a period of at least two weeks to preclude recol-
lection of the values. This was the first part of the study.
Usually the echocardiographic measurements are made
by a cardiologist who stores 3 images, each representing 3
heart cycles. Each image is accompanied by the corre-
sponding ECG. The cardiologist chooses one of the 3 on-
sets of the QRS wave of the ECG in 1 of the 3 images for
measurement of the diastolic wall thickness which he con-
siders appropriate for measurement. This procedure is
based on the presumption that the variation between the
M-mode images is of no influence on the measurement of
the wall thickness. If this presumption would not be true,
exclusion of this source of variation might improve the re-
producibility of the measurement. Therefore we designed
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the second part of the study, in which observers 1 and 2
assessed one specific pre-selected image from each of
twenty echocardiograms twice with a period of at least
two weeks in between. The 20 echocardiograms were se-
lected based on the range of Z-scores of IVSd, LVPWd
and LVEDd to represent the entire range of the wall thick-
ness in the patient population. From each echocardio-
gram, observer 2 selected one exact point of one heartbeat
cycle in 1 image. Both observers measured IVSd, LVPWd
and LVEDd at exactly the same point in that specific
image three times and the mean was calculated.
Statistical analysis
Intra- and inter-observer reproducibility of the continuous
measures IVSd, LVEDd, LVPWd and LVMI was assessed
by the Bland Altman method. The limits of agreement
(LoA) are calculated as the mean difference in scores of
repeated measurements (mean) ± 2 × standard deviation
of these differences (SDdiff ) [24]. The variability of the
measurement is also reported as Smallest Detectable
Change (SDC), calculated as 1.96 × √2 × standard error of
measurement (SEM). SEM is the square root of the error
variance calculated by analysis of variance (ANOVA). SDC
reflects the smallest within-person change in score that,
with P < 0.05, can be interpreted as a “real” change, above
measurement error, in one individual (SDCind) [24].
Cohen’s kappa was calculated to assess intra- and
inter-observer agreement for dichotomous variables, i.e.
presence or absence of LVH. The interpretation of kappa
is arbitrary. A value of 0.70 is generally recommended as a
minimum standard for reliability [25].
Results
Ninety-two children with ESRD (0–18 years old) were
included. Fifty one (55%) were boys; the median (range)
age, weight and BSA were 13.1 (0.7- 19.1) years, 37.8
(4.3- 96.0) kg and 1.2 (0.4- 2.2) m2, respectively (Table 1).
The median (range) duration of RRT was 1.8 (0–6.8)
years. At time of the echocardiography, 26 children
(28%) were treated with hemodialysis, 24 (26%) with
peritoneal dialysis and 42 (46%) were transplanted.
All 4 observers (the original analyst, observers 1, 2 and 3)
agreed in 2 patients diagnosing LVH and in 46 patients by
diagnosing non LVHWT. In Table 2 we compared the
demographics for these 48 children the observers agreed
on vs. the other 44 children the observers could not agree
on the diagnosis LVHWT or no-LVHWT (Table 2). There
were no significant differences found between the 2 groups
The results of the intra- and inter-observer reproduci-
bility are shown in Table 3.
The IVSd and LVPWd measurements of observer 2
were consistently smaller than those of observers 1 and 3.
The intra-observer SDCs ranged from 1.6 to 1.7 mm, from
2.0 to 2.6 mm, from 2.8 to 6.9 mm and from 17.7 to
30.5 g/m2 for IVSd, LVPWd, LVEDd and LVMI, respect-
ively. The intra-observer kappas for the 3 observers for
LVHWT and LVHMI ranged from 0.4 to 1.0 and from 0.5
to 0.6, respectively.
The inter-observer SDCs were 2.6 mm, 2.9 mm,
5.9 mm and 24.6 g/m2 for IVSd, LVPWd, LVEDd and
LVMI, respectively. The inter-observer kappas for
LVMWT and LVHMI ranged from 0.1 to 0.4 and from 0.3
to 0.5, respectively.
Selected image of 20 selected patients
From the 20 children whose echocardiograms were se-
lected for the second part of the study, 10 (50%) had
been diagnosed with LVHWT by the original observer.
The results of the intra- and inter-observer reproducibil-
ity study are shown in Table 4.
None of the reproducibility results were superior to
those of the first part of the study, in which each obser-
ver chose the images to be measured.
The results of the assessment of diagnosing LVH by
the original analyst, observers 1, 2 and 3 of all 92 echo-
cardiograms are shown in Table 5. The prevalence of
LVHWT and LVHMI ranged from 2 to 30% and from 8 to
25% of the 92 patients, respectively. All 4 observers (the
original analyst, observers 1, 2 and 3) agreed in 46 pa-
tients and 56 patients by diagnosing non LVHWT and
non LVHMI, respectively. All 4 observers agreed in 2 pa-
tients and in 6 patients by diagnosing LVHWT and
LVHMI, respectively. Use of the LVHWT definition
resulted in a higher prevalence for two observers and a
lower prevalence for the other two observers and vice
versa, indicating that there is not a simple relation be-
tween the two definitions.
Table 1 Demographics of children with End-stage renal
disease at time of the Echocardiography
Children with ESRD
(n=92)
Age (years) 13.1 (0.7-19.1)
Male* 51 (55%)
Weight (kilograms) 37.8 (4.3-96.0)
BSA (m2) 1.2 (0.4-2.2)
Height (cm) 138 (61–184)
Duration of RRT (years) 1.8 (0.0-6.8)
Modality at time of Echocardiography*
-Hemodialysis 26 (28%)
-Peritoneal dialysis 24 (26%)
-Transplantation 42 (46%)
Data are presented as median (range), *Data are presented as n (%), BSA Body
surface area.
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Discussion
We found a low reproducibility of the measurement of
ventricular wall thickness, and as a result low agreement
within and between observers in diagnosing LVH using
conventional echocardiography in children with ESRD.
The inaccurateness of the wall thickness measurements
affects LVH assessment for all different definitions of
LVH. Our data demonstrate that in individual children,
changes in diastolic wall thickness or LVMI as a result
of ESRD which are expected over a period of a year can-
not be distinguished from measurement error, even
when measured by the same observer.
With more than 30 years of clinical use, echocardiog-
raphy has become one of the most important non-invasive
imaging methods in the evaluation of cardiac morphology
and dynamics. It is generally considered a valuable method
for the detection of LVH, due to its wide availability, non-
invasiveness, and relatively low cost. However, in children
the interpretation of echocardiographic data is hampered
by various problems.
First, according to our study, the variability of outcomes
even within one experienced observer is of such magni-
tude that expected changes in wall thickness can not reli-
ably be monitored reliably. The intra-and inter-observer
SDCs of the echocardiographic measurement of the IVSd
and the LVPWd ranged from 1.6 to 2.6 mm and 2.0 to 2.9
mm, respectively. In an individual child only changes in
septum or wall thickness larger than the SDC can be con-
sidered as “real change”. Since in children the normal
values of IVSd and LVPWd are small, ranging from 3 to
10 mm and from 3 to 13 mm respectively, changes over
time in an individual child need to be as large as 16 to
100% of the normal value before they can be considered
as “real change”, i.e., not due to measurement variability.
The intra-and inter-observer SDC of the LVMI ranged
from 17.7 to 30.5 g/m2. Similarly, since in children the
normal values of LVMI are 40 to 80 g/m2, changes over
time in an individual child need to be as large as 30-60%
of the normal value before they can be considered as
“real change”.
Secondly, there is little consensus about the definition
of LVH in children. In adults LVH is usually defined as
LVMI > 51 (g/m2.7), which is associated with increased
cardiovascular morbidity and mortality [26]. In children,
LVH is based on the normal distribution of LVMI or wall
thickness in healthy children, because cardiovascular out-
come studies in children are lacking due to the low inci-
dence of cardiovascular events. Some physicians define
LVH as LVM according to Devereux corrected for body
size above a cutoff value (> 51 g/m2.7 or 38.6 g/m2.7) or
above the P95 of healthy children for age. Yet, different in-
dexations with respect to body size are used. All these dif-
ferent indexes for LVM lead to important differences in
LVH prevalence, varying from 18% to 55% in children with
chronic kidney disease [20] and from 27% to 52% in chil-
dren on peritoneal dialysis [19]. In 2009 Khoury et al.
reported normal values for LVM indexed for height in
children between 0 and 18 years of age [18]. As LVM
indexed for weight or BSA had been found not to be ac-
curate in children with obesity [27], it is conceivable that
Khoury’s normal values are not applicable in growth-
retarded (ESRD) children either. Borzych et al. showed
that when using the Khoury charts, LVH prevalence was
significantly higher in growth-retarded children on peri-
toneal dialysis than in children on peritoneal dialysis of
normal height [19]. Another approach to the definition of
LVH is using z-scores of only the septal and/or posterior
wall thickness as measure for LVH. In this definition, the
effect of changes in left ventricular end-diastolic volume is
neglected. Since ventricular dilatation leads to wall thin-
ning, LVH may be missed in dilated cardiomyopathy by
this method. In the present study we used LVM indexed
Table 2 Demographics of children who were diagnosed with LVHWT or no LVHWT by all 4 observers vs. all children
were there was no agreement (n=44)
All agree on LVHWT or no LVHWT No agreement on LVHWT or no LVHWT P
valuen=48 n=44
Age (years) 12.6 (1.4-18.3) 14.0 (0.7-19.1) 0.23a
Male* 23 (49%) 28 (62%) 0.14b
Weight (kilograms) 33.0 (4.3-96.0) 41 (7.0-88.5) 0.44a
BSA (m2) 1.2 (0.4-2.2) 1.3 (0.4-2.1) 0.43a
Height (cm) 145 (85–181) 153 (69–184) 0.52a
Duration of RRT (years) 1.6 (0–6.8) 1.7 (0–5.9) 0.70a
Modality at time of Echocardiography* 0.54 b
-Hemodialysis 14 (29%) 12 (27%)
-Peritoneal dialysis 11 (23%) 13 (30%)
-Transplantation 23 (48%) 19 (43%)
Data are presented in median (range), * Data are presented as n (%), RRT renal replacement therapy, a mann-Withney U, b chi square test.
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for BSA because in our opinion height and weight allow a
better estimation of lean body mass, and therefore heart
size, than height2.7 in children with possible growth re-
tardation [17].
Our results are in line with other studies. In two stud-
ies in healthy children, intra-observer variance was
found to be smaller than inter-observer variance, as is
usually the case [28,29]. In the study by Schieken et al.
[28] the intra-observer SDC was 1.7 mm for both IVSd
and LVPWd. An explanation for this relatively high repro-
ducibility might be that the data from the Schieken et al.’s
study were derived from a selection of 20 out of 28 echo-
cardiograms, which satisfied the criteria for technical ac-
ceptability. Inter-observer SDCs were comparable with
our findings. In the study by Day et al. [29] the intra-
observer mean differences were equal to those found in
our study, but the inter-observer mean differences were
considerably larger. Still, the authors concluded that “the
Table 3 Intra- and inter-observer reproducibility of echocardiographic measurements
Intra-observer Observer 1 Observer 2 Observer 3
IVSd (mm) Median (range) 7.0 (3.8-11.0) 6.1 (3.8-10.5) 6.9 (3.7-12.8)
Mean diff. [95% CI] 0.2 [0.0-0.4] 0.1 [0.0-0.3] 0.1 [−0.1-0.3]
LoA −1.6-1.9 −1.4-1.7 −1.6-1.8
SDC 1.7 1.6 1.7
LVPWd (mm) Median (range) 7.0 (4.2-12.0) 5.9 (3.4-10.7) 7.9 (4.1-14.2)
Mean diff. [95% CI] 0.4 [−0.1-0.7] 0.3 [−0.3-0.8] 0.1 [−0.1-0.4]
LoA −2.1 - 2.9 −1.1-1.7 −2.0 -2.1
SDC 2.5 2.0 2.6
LVEDd (mm) Median (range) 41 (21–59) 44 (23–63) 41 (20–57)
Mean diff. [95% CI] 0.9 [0.2-3.2] 0.2 [−0.8-0.5] 0.2 [−0.3-0.6]
LoA −6.1 - 7.9 −2.7- 3.1 −4.3 - 4.4
SDC 6.9 2.8 4.4
LVMI Median (range) 76 (34–219) 70 (39–181) 80 (31–255)
(g/m2) Mean diff. [95% CI] 1.1 [−2.1-4.3] 0.7 [−1.2-2.5] 0.7 [−1.5-2.9]
LoA - 30.1 – 32.3 −17.4 – 18.8 −20.5 – 21.9
SDC 30.5 17.7 20.7
LVHWT Kappa [95% CI] 0.4 [0.2-0.7] 1.0 [1.0-1.0] 0.4 [0.2-0.6]
LVHMI Kappa [95% CI] 0.6 [0.4-0.8] 0.6 [0.3-0.9] 0.5 [0.3-0.7]
Inter-observer Observer 1 vs 2 Observer 1 vs 3 Observer 2 vs 3
IVSd (mm) Mean diff. [95% CI] 1.0 [0.7-1.2] 0.1 [0.0-0.3] 1.1 [0.9-1.3]
LoA 1.3 – 3.3 −1.6 - 1.8 −1.1 – 3.3
SDC (3 observers) 2.6
LVPWd (mm) Mean diff. [95% CI] 1.0 [0.8-1.2] 0.6 [0.4-0.8] 1.6 [1.3-1.8]
LoA −1.0 – 3.0 −1.4 – 2.4 −0.8 – 3.9
SDC (3 observers) 2.9
LVEDd (mm) Mean diff. [95% CI] 2.4 [1.9-2.9] 0.3 [−0.4-1.0] 2.7 [2.0-3.4]
LoA −2.1 – 6.9 - 6.4 - 7.2 - 3.8 – 9.3
SDC (3 observers) 5.9
LVMI (g/ m2 ) Mean diff. [95% CI] 6.5 [3.9-9.2] 4.0 [1.6-6.4] 10.6 [7.8-13.3]
LoA −6.2 – 31.9 −19.1 – 27.2 - 15.7 – 37.2
SDC (3 observers) 24.6
LVHWT Kappa [95% CI] 0.1 [−0.2-0.5] 0.4 [0.2-0.6] 0.1 [−0.2-0.4]
LVHMI Kappa [95% CI] 0.3 [0.1-0.5] 0.5 [0.3-0.7] 0.4 [0.2-0.7]
Part 1 (n=92).
IVSd diastolic interventricular septum, LVEDd left ventricular end-diastolic diameter, LVPWd diastolic left ventricular posterior wall thickness, LVMI left ventricular
mass index, Mean diff, mean difference, CI confidence interval, LoA limits of agreement, SDC smallest detectable change, LVHWT was defined as a Z-score of IVSd
and\or LVPWd > + 2 (according to normal values of healthy Dutch children), LVHMI was defined as LV mass index (g/m
2) > 103 g/m2 for boys and > 84 g/m2
for girls.
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echocardiographic measurements taken from healthy chil-
dren in a longitudinal study can be made accurately with
acceptable reproducibility”.
The reproducibility of the LV mass is highly dependent
on the reproducibility of IVSd and LVPWd. In M-mode
measurements, differences of IVSd and LVPWd of ap-
proximately 5% may be translated into differences in LV
mass between 8% and 15%, which may represent about
50 g in adults [30]. Thus, measurement inaccuracies in
individual adult patients limit the use of the Devereux
formula to calculate LV mass [30]. Test-retest studies in
adults indeed found differences of up to 30 g between
tests [31,32]. Therefore the authors of ‘the reliability of
M-Mode echocardiography studies’ (the RES trial) con-
cluded that the probability of a true change in LV mass
over time is maximized for a single-reader difference
greater than 18% of the initial value.
Theoretically there are several sources of variability that
can influence echocardiographic measurements. In our
study the following sources of variation were excluded by
the design of offline assessment of the non-moving stored
images: placing of the echocardiogram probe, the way the
images are captured and obviously within-patient variabil-
ity like day-to-day variability in fluid status (e.g. before or
after dialysis) and blood pressure. To minimize other
sources of variation, such as timing in the cardiac cycle, all
measurements were made according to the Guidelines and
Standards for Performance of a Pediatric Echocardiogram
of the American Society of Echocardiography7. In these
guidelines, the exact choice of the images and heart cycles
within one assessment on which the calculations are based
is not defined. We therefore adjusted the protocol in part
two of the study to exclude any potential variability due to
the choice of the image and heart cycle. This did not lead
to improvement of the reproducibility results, indicating
that the variability is inherent in the measurement proced-
ure, and not due to the choice of the particular image.
To improve reproducibility the standard method is to
measure multiple heart cycles and calculate the mean
value, as was done in our study. In addition, some authors
even advise interpretation by more than one cardiologist
[33]. Others, however, advise that the same cardiologist
reads all the echocardiograms for an individual patient to
reduce the variability of the longitudinal measurements
[34]. This is unfortunately not supported by the low intra-
observer reproducibility that we found. In 2010 Lopez
et al. developed recommendations for quantifications dur-
ing the performance of a pediatric echocardiogram [35].
However, these recommendations are based on 2D or 3D
short axis imaging, while in Europe M-mode echocardiog-
raphy is still the most used technique. To date, it has to be
Table 4 Intra- and inter-observer reproducibility based on
identical images
Intra-observer Observer 1 Observer 2
IVSd (mm) Median (range) 7.5 (4.2-11.9) 7.4 (3.7-11.6)
Mean diff. (95% CI) 0.2 (−0.2- 0.6) 0.4 (0.0-0.8)
LoA −1.4-1.8 −1.2-2.1
SDC 1.6 1.8
LVPWd (mm) Median (range) 6.9 (3.9-12.3) 7.1 (4.0-11.3)
Mean diff. (95% CI) 0.4(−0.3-1.1) 0.5 (0.1-0.9)
LoA −2.5-3.4 −1.3-2.3
SDC 3.3 2.0
LVEDd (mm) Median (range) 43.2 (26.3-57.2) 43.9 (26.3-57.2)
Mean diff. (95% CI) 0.4 (−0.3-1.0) 0.6 (0.1-1.1)
LoA −2.6-3.3 −1.6-4.9
SDC 2.9 2.2
LVMI Median (range) 79 (45–226) 82 (47–221)
(g/m2) Mean diff. (95% CI) 4.0 (−1.4-9.4) 4.7 (0.8-8.7)
LoA −19.2-27.2 −12.2-21.7
SDC 22.8 16.6
Inter-observer Observer 1 vs 2
IVSd (mm) Mean diff (95% CI) 0.4 (0.0-0.7)
LoA −1.1-1.9
SDC 1.6
LVPWd (mm) Mean diff. (95% CI) 0.3 (−0.1-0.8)
LoA −1.57-2.25
SDC 1.9
LVEDd (mm) Mean diff. (95% CI) 1.5 (0.7-2.3)
LoA −2.0-4.9
SDC 3.4
LVMI Mean diff. (95% CI) 0.1 (−5.3-5.6)
(g/m2) LoA −23.3-23.5
SDC 22.9
Part 2 (n=20).
IVSd diastolic interventricular septum, LVEDd left ventricular end-diastolic
diameter, LVPWd diastolic left ventricular posterior wall thickness, LVMI Left
ventricular mass index, Mean diff mean difference, CI confidence interval, LoA
limits of agreement, SDC smallest detectable change.
Table 5 Prevalence of LVH according to different
definitions and different observers
Observer LVHWT^ (%) LVHMI
# (%) Kappa
between
LVHWT
and
LVHMI
n=92 n=92
Original analyst* 28 (30%) 22 (24%) 0.62
1 20 (22%) 23 (25%) 0.46
2 2 (2%) 7 (8%) 0.42
3 27 (29%) 22 (24%) 0.42
*The treating cardiologist who made the echocardiogram, LVH left ventricular
hypertrophy, ^LVHWT was defined as a Z-score of IVSd and/or LVPWd > + 2
(according to normal values of healthy Dutch children), #LVHMI was defined as
LV mass index >103 g/m2 for boys and >84 g/m2 for girls.
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established if 2D or 3D echocardiography is indeed bet-
ter reproducible than M-mode echocardiography. Mag-
netic resonance imaging (MRI) of the heart could be
valuable for diagnosing LVH, as it is more accurate and
reproducible than echocardiography [36]. It can be used
to precisely estimate a patient's left ventricular mass
and assess other structural cardiac abnormalities. Con-
trary to echocardiography, MRI has several disadvan-
tages that preclude its use in daily clinical practice. It is
expensive, time consuming, not easily accessible and
obviously not bed side. Furthermore, in young children
sedation is often necessary.
A limitation of this study is that the original echocardio-
grams were assessed retrospectively without the original
observers knowing this would be a reproducibility study.
The observers 1, 2 and 3 were aware of the fact this was a
reproducibility study. This could be an explanation of the
differences between the original observer and the other
observers. Another limitation of this retrospective design
is that not all original echocardiograms were performed at
equal time intervals after a hemodialysis session for the 26
children on hemodialysis. Although the reproducibility
measurements were assessed by the exact same offline im-
ages, the wall thickness could be affected by fluid overload.
Finally, although observers 1, 2 and 3 used the same de-
vice to evaluate the images, we cannot exclude potential
variation due to the use of the Vivid 7 or Philips Sonos
5500 for the original echocardiography.
Furthermore, Cohen’s kappa gives a quantitative as-
sessment of how well two raters agree corrected for
chance agreement. The interpretation of kappa is arbi-
trary. Several difficulties have been described with the
interpretation of kappa, however, one of which is related
to the prevalence of the condition [37,38]. If only the
most severe cases are diagnosed as LVH as was done by
observer 2, the intra-observer kappa is inflated.
Conclusions
Our study has important clear implications. The need for
cardiovascular monitoring in children with ESRD is be-
yond discussion. Timely detection of left ventricular ab-
normalities may decrease the risk for early cardiac death
by therapeutic adjustments such as more frequent dialysis,
conversion from peritoneal dialysis to (frequent) hemo-
dialysis, dietary measures or adjustment of medication. In
this respect, routinely yearly echocardiography in children
with ESRD has been promoted. Yet we believe that LVH
assessment by conventional echocardiography in an indi-
vidual child with ESRD may too easily result in either
underreporting of LVH or in an spurious diagnosis of
LVH. This may either lead to a potentially preventable de-
terioration of cardiac function or to unnecessary interven-
tions with potential burdens for the patient. We therefore
believe that new, more sensitive tools (e.g. MRI, 3D
echocardiography, Tissue Doppler imaging and Speckle
Tracking Echocardiography) need to be explored as reli-
able tools for longitudinal cardiac follow-up in these
children.
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